Thermo Fisher Adds to Specialty-Dx Business with $3.5B Phadia Buy
May 20, 2011
Thermo Fisher Adds to Specialty-Dx Business with $3.5B Phadia Buy
The acquisition, expected to close in the fourth quarter, will give Thermo Fisher Phadia's immunoassay-based allergy testing and autoimmune disease-testing products.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.